• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Nemaura uplists shares to NASDAQ exchange

January 23, 2018 By Sarah Faulkner

NemauraNemaura Medical (OTC:NMRD) said today that shares of its common stock were approved to list on the NASDAQ exchange.

The medtech company’s shares are slated to start trading on Jan. 25 under its existing symbol.

Nemaura, which is developing a wireless continuous glucose monitor, finished its clinical trial program in Europe late last year and is seeking CE Mark clearance for a product launch in the U.K.

“Our listing on NASDAQ is a major corporate milestone which builds upon the technical and clinical progress we have made over the past few years,” CEO Faz Chowdhury said in prepared remarks. “The listing coincides with the successful completion of our European clinical program and will help broaden our shareholder base, improve liquidity, and provide increased visibility and greater exposure to the institutional investor community, ultimately contributing to increasing shareholder value.”

The England-based company said it has inked commercial deals with groups in Europe and Australia, and is reportedly in talks with multiple groups for licensing and marketing rights in other territories.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Diabetes, Featured, Wall Street Beat Tagged With: Nemaura Medical

IN CASE YOU MISSED IT

  • Nuvo, Sheba Medical Center develop AI-powered gestational diabetes management platform
  • Verily’s Onduo, Sword Health collaborate on virtual diabetes care
  • Shareholder lawsuit over BD’s Alaris pumps recall moves forward
  • Embecta stock soars on first full-quarter results after BD spinoff
  • Abbott will spend $450M to up FreeStyle Libre production in Ireland

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS